Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Retained Earnings (2016 - 2025)

Cytokinetics (CYTK) has disclosed Retained Earnings for 16 consecutive years, with -$3.5 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings changed N/A to -$3.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.5 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$3.5 billion for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was -$3.5 billion at Cytokinetics, down from -$3.3 billion in the prior quarter.
  • The five-year high for Retained Earnings was -$10000.0 in Q4 2023, with the low at -$3.5 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$1.5 billion, with a median of -$1.3 billion recorded in 2022.
  • The sharpest move saw Retained Earnings crashed 5937645.45% in 2022, then skyrocketed 99.97% in 2024.
  • Over 5 years, Retained Earnings stood at -$1.2 billion in 2021, then surged by 99.7% to -$3.6 million in 2022, then soared by 99.72% to -$10000.0 in 2023, then crashed by 25999900.0% to -$2.6 billion in 2024, then crashed by 34.62% to -$3.5 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$3.5 billion, -$3.3 billion, and -$3.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.